Article Text

Download PDFPDF

#164 Impact of enhanced recovery after surgery (ERAS) in the return to intended oncologic treatment in patients with advanced ovarian cancer
  1. Úrsula Acosta,
  2. Catalán Sara,
  3. Luzarraga Anna,
  4. Míguez Marta,
  5. Assumpciò Pérez-Benavente and
  6. Jose Luis Sánchez-Iglesias
  1. Vall d’Hebron University Hospital, Barcelona, Spain


Introduction/Background Treatment of advanced ovarian cancer (AOC) consists of surgery followed by chemotherapy (CT). Optimal time between surgery and start of CT is unknown, but delays could harm survival. Intensified recovery after surgery (ERAS) programs reduce hospital stay without increasing morbimortality after surgery for gynecological cancer. We hypothesized that ERAS protocols in patients undergoing surgery for AOC allow earlier initiation of CT and therefore improve survival.

Methodology Retrospective cohort study including patients with ovarian, tubal, or primary peritoneal cancer of any histology, FIGO stages IIB-IV, undergoing primary (PDS), interval (IDS), or secondary (SDS) debulking surgery, who received adjuvant CT at Vall d’Hebron Hospital (Spain). We compared patients who followed an ERAS protocol between 2018 and 2021 and and those who followed conventional management (CONV) between 2014 and 2018. Time from surgery to CT, completion of treatment, adherence to ERAS, overall survival (OS) and disease-free survival (DFS) were compared.

Results We included 137 patients in the ERAS group and 46 in the CONV. CT started at a median of 44.5 days in the ERAS group and 48.5 in the CONV. There were no differences in CT onset time by type of surgery. CT was completed by 80.3% in the ERAS group and 84.8% in the CONV. No correlation between adherence to ERAS and CT onset time was observed. There were no differences in OS and DFS between groups.

Conclusion We couldn’t demonstrate that patients who follow an ERAS protocol after surgery for AOC start CT earlier than those who don’t, nor have differences in survival been observed. Also, a relationship between adherence and an earlier onset of CT wasn’t observed. This is the first study to evaluate the time to oncological treatment after PDS, IDS or SDS for AOC after the implementation of an ERAS protocol, and comparing it with a control group.

Abstract #164 Table 1

Characteristics of the study groups.

Disclosures Authors declare no disclosures.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.